SANTA CLARA, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for the iFuse Bedrock Granite™ (Granite) system, used for pelvic fixation and sacroiliac joint fusion in conjunction with lumbar spinal fusion procedures, under the Medicare Hospit ...

Si-Bone (SIBN) shares rallied 6.9% in the last trading session to close at $13.11. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 12.2% loss over the past four weeks. Si-Bone scored a strong price increase, on investors' optimism surrounding its impending third-quarter 2024 financial results, which is slated to release on Nov. 12 post the closing bell. The Zacks Consensus Estimate for the third quarter reven ...

Company Overview - SI-BONE, Inc. is a global leader in technology for the surgical treatment of sacropelvic disorders [2] - The company has supported over 3,900 surgeons in performing more than 100,000 sacropelvic procedures since pioneering minimally invasive surgery of the SI joint in 2009 [2] - SI-BONE has a strong clinical evidence base, including two randomized controlled trials and over 135 peer-reviewed publications [2] Upcoming Financial Results - SI-BONE will report its financial results for the third quarter of 2024 after market close on November 12, 2024 [1] - A conference call will be hosted by management at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day [1] - Investors can access the live audio of the webcast through the company's website, and it will be archived for at least 90 days [1]

SI-BONE, Inc. (SIBN) announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT Implant System (TNT), on Thursday. TNT received the FDA's 510(k) clearance and was awarded Breakthrough Device Designation by the FDA in August 2024. Per SI-BONE, TNT, which has been designed to address the anatomic and biomechanical challenges of pelvic fragility fractures (particularly in patients with poor bone quality), is expected to offer a significant advancement over traditional can ...

SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™ Implant System (TNT). Designed to address the anatomic and biomechanical challenges of pelvic fragility fractures, particularly in patients with poor bone quality, TNT offers a significant advancement over t ...

Shares of Si-Bone (SIBN) have gained 2.4% over the past four weeks to close the last trading session at $16.55, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $23.22 indicates a potential upside of 40.3%. The mean estimate comprises nine short-term price targets with a standard deviation of $4.68. While the lowest estimate of $18 indicates an 8.8% increase from the current pric ...

SANTA CLARA, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510(k) clearance of the iFuse TORQ TNT™ Implant System (TNT). The TNT implant system is designed to meet the specific anatomical and bone mineral density needs of the sacrum and ilium and will serve as the next generation technology for pelvic fragility fracture fixation and sacroiliac joint fusi ...

Si-Bone (SIBN) closed the last trading session at $14.12, gaining 4.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $23.22 indicates a 64.5% upside potential. The average comprises nine short-term price targets ranging from a low of $18 to a high of $32, with a standard deviation of $4.68. While the lowest estimate indicates an increase of 27.5% from the current price level, the ...

SANTA CLARA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will be participating in the upcoming 2024 Canaccord Genuity 44th Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 14th, 2024, at 3:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://url.us ...

Core Insights - SI-BONE, Inc. will report its financial results for Q2 2024 on August 5, 2024, after market close, with a conference call scheduled for 1:30 p.m. Pacific Time [1] Company Overview - SI-BONE, Inc. is a leader in surgical technology for treating musculoskeletal disorders of the sacropelvic anatomy, having pioneered minimally invasive surgery of the SI joint since 2009 [5] - The company has supported over 3,700 surgeons in performing more than 100,000 sacropelvic procedures, backed by clinical evidence from four randomized controlled trials and over 130 peer-reviewed publications [5] - SI-BONE has expanded its offerings to adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma [5]